Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × enasidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 22 Myelodysplastic Syndromes 5 Leukemia, Myelomonocytic, Chronic 5 Myeloproliferative Disorders 3 Leukemia 3 Hematologic Neoplasms 3 Primary Myelofibrosis 2 Neoplasms 2 Multiple Myeloma 2 Leukemia, Myeloid 2 Chondrosarcoma 2 Thrombocytosis 1 Sinonasal undifferentiated carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic-Myeloproliferative Diseases 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Accelerated Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Monocytic, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04092179 2024-01-24

ENAVEN-AML

University Health Network, Toronto

Phase 1/2 Terminated

Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡